All News



Rutgers Partners with Horizon Discovery to Develop a New Gene Editing Technology

Published: January 28, 2019

Rutgers University has partnered with Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, to develop a new technique built on CRISPR.

Originally developed by Shengkan "Victor" Jin, associate professor of pharmacology in the Robert Wood Johnson Medical School at Rutgers, and Juan Carlos Collantes, currently a pharmacology postdoctoral fellow, the technique allows for safer and more effective gene editing than existing CRISPR methods, and has the potential to develop new therapies for sickle cell anemia, HIV, leukemia and more.

Gene editing technology has truly revolutionised how scientists think about their search for better options and outcomes in the treatment of disease. We look forward to advancing the shared goals of further developing this novel base editing platform and improving human health through this collaboration with Horizon.

— S. David Kimball, PhD, Interim Senior Vice President for Research and Economic Development at Rutgers University

Part of this project's funding came from the TechAdvance Fund, an early-stage-technology fund that provides financial support and business expertise for Rutgers faculty and students to advance promising technologies toward commercialization.

To view the full press release, visit the source link below.

SourceORED News Page.

Header image couresy of Wikipedia